NDA 020527 · Wyeth Pharms
Prempro
Estrogens, Conjugated, Medroxyprogesterone Acetate · Oral-28 · Estrogen
Last checked: Nov 20, 2026Latest source record: Apr 22, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1995
Nov 17, 1995
Approved uses
4
Original approval plus efficacy supplements
Registered trials
1,166
241 Phase 3, 150 recruiting
FAERS reports
23,488
19,848 serious, 648 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: CARDIOVASCULAR DISORDERS, BREAST CANCER, ENDOMETRIAL CANCER and PROBABLE DEMENTIA Estrogen Plus Progestin Therapy Cardiovascular Disorders and Probable Dementia Estrogen plus progestin therapy should not be used for the prevention of cardiovascular disease or dementia [see Warnings and Precautions (5.1 , 5.3) , and Clinical Studies (14.6 , 14.7) ] . The Women's Health Initiative (WHI) estrogen plus progestin substudy reported an increased risk of deep vein thrombosis (DVT), pulmonary embolism (PE), stroke and myocardial infarction (MI) in postmenopausal women (50 to 79 years of age) during 5.6 years of treatment with daily oral conjugated estrogen (CE) (0.625 mg) combined with medroxyprogesterone acetate (MPA) (2.5 mg), relative to placebo [see Warnings and Precautions (5.1) , and Clinical Studies (14.6) ] . The WHI Memory Study (WHIMS) estrogen plus progestin ancillary study...
What it is approved for
From the label in effect Apr 28, 2026.
PREMPRO/PREMPHASE is an estrogen plus progestin indicated in a woman with a uterus for: • Treatment of Moderate to Severe Vasomotor Symptoms due to Menopause ( 1.1 ) • Treatment of Moderate to Severe Vulvar and Vaginal Atrophy due to Menopause ( 1.2 ) • Prevention of Postmenopausal Osteoporosis ( 1.3 ) 1.1 Treatment of Moderate to Severe Vasomotor Symptoms due to Menopause 1.2 Treatment of Moderate to Severe Vulvar and Vaginal Atrophy due to Menopause 1.3 Prevention of Postmenopausal Osteoporosis
Mechanism: Endogenous estrogens are largely responsible for the development and maintenance of the female reproductive system and secondary sexual characteristics. Although circulating estrogens exist in a dynamic equilibrium of metabolic interconversions, estradiol is the principal intracellular human estrogen and is substantially more potent than its metabolites, estrone and estriol, at the receptor level. The primary source of estrogen in normally cycling adult women is the ovarian follicle, which secretes 70 to 500 mcg of estradiol daily, depending on the phase of the menstrual cycle. After...
Therapeutic areas: Endocrinology and women's health
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jun 4, 2003 Supplement 24 · Efficacy LabelReviewLetter
- Mar 12, 2003 Supplement 17 · Efficacy ReviewLetterLabel
- Jan 9, 1998 Supplement 6 · Efficacy ReviewLetter
- Nov 17, 1995 Original approval · Type 3 - New Dosage Form Other Important Information from FDA
5 products under this application
- PREMPRO · ESTROGENS, CONJUGATED 0.625MG; MEDROXYPROGESTERONE ACETATE 5MG · TABLET, ORAL-28 · Prescription
- PREMPRO · ESTROGENS, CONJUGATED 0.625MG; MEDROXYPROGESTERONE ACETATE 2.5MG · TABLET, ORAL-28 · Prescription
- PREMPRO · ESTROGENS, CONJUGATED 0.45MG; MEDROXYPROGESTERONE ACETATE 1.5MG · TABLET, ORAL-28 · Prescription
- PREMPHASE 14/14 · ESTROGENS, CONJUGATED 0.625MG,0.625MG; MEDROXYPROGESTERONE ACETATE N/A,5MG · TABLET, ORAL-28 · Prescription
- PREMPRO · ESTROGENS, CONJUGATED 0.3MG; MEDROXYPROGESTERONE ACETATE 1.5MG · TABLET, ORAL-28 · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Estrogens" as an intervention, any sponsor and status, largest first.
- Genetic Testing or Clinical Assessment in Determining the Need for Chemotherapy in Women With Breast Cancer That Involves No More Than 3 Lymph NodesPivotal-lookingCompleted
European Organisation for Research and Treatment of Cancer - EORTCResearch network
NCT00433589 · 6,600 participants (planned) · Start Feb 2007 · Primary completion Mar 2020
Drug: anthracycline-based; docetaxel and capecitabine and 2 more · For: Breast Cancer
Sites: Amsterdam, Netherlands
- An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)Pivotal-lookingActive, not recruiting
AstraZenecaAstraZeneca (AZN)
NCT05952557 · 5,511 participants · Start Oct 5, 2023 · Primary completion Mar 4, 2030
Drug: Camizestrant; Tamoxifen and 4 more · For: Breast Cancer, Early Breast Cancer
Sites: Dothan, Alabama; Phoenix, Arizona; Tucson, Arizona · 661 sites in all
The Third Xiangya Hospital of Central South UniversityAcademic, hospital or other
NCT07421908 · 5,000 participants (planned) · Start Mar 1, 2025 · Primary completion Mar 1, 2030
Drug: Traditional Chinese medicine for tonifying the kidney · For: Intrauterine Adhesion
Sites: Changsha, China
- A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of RecurrencePivotal-lookingActive, not recruiting
Stemline Therapeutics, Inc.Industry
NCT06492616 · 4,556 participants · Start Sep 27, 2024 · Primary completion Aug 2029
Drug: Elacestrant; Anastrozole and 3 more · For: Breast Cancer
Sites: Daphne, Alabama; Chandler, Arizona; Gilbert, Arizona · 555 sites in all
- Trial of Perioperative Endocrine Therapy - Individualising CarePivotal-lookingActive, not recruiting
Institute of Cancer Research, United KingdomAcademic, hospital or other
NCT02338310 · 4,486 participants · Start Sep 2008 · Primary completion Apr 2024
Drug: Aromatase Inhibitors · For: Breast Cancer
Sites: Dundonald, United Kingdom; Slough, United Kingdom; Aylesbury, United Kingdom · 128 sites in all
- A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine TherapyPivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT05774951 · 4,300 participants (planned) · Start Mar 31, 2023 · Primary completion Apr 20, 2027
Drug: Camizestrant; Tamoxifen and 3 more · For: Breast Cancer, Early Breast Cancer
Sites: Birmingham, Alabama; Dothan, Alabama; Anchorage, Alaska · 709 sites in all
- Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast CancerPivotal-lookingCompleted
NSABP Foundation IncResearch network
NCT01547741 · 4,242 participants · Start Apr 2012 · Primary completion May 31, 2022
Drug: Doxorubicin; Cyclophosphamide and 2 more · For: Breast Cancer
Sites: Anchorage, Alaska; Phoenix, Arizona; Scottsdale, Arizona · 915 sites in all
- A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)Pivotal-lookingActive, not recruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT04961996 · 4,170 participants · Start Aug 27, 2021 · Primary completion Aug 8, 2025
Drug: Giredestrant; Physician's Choice of Endocrine Therapy and 1 more · For: Early Breast Cancer
Sites: Daphne, Alabama; Bakersfield, California; Fullerton, California · 621 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- breast cancer7,889
- breast cancer female5,791
- breast cancer metastatic1,505
- drug ineffective738
- cerebrovascular accident502
- depression478
- headache426
- anxiety418
- nausea414
- deep vein thrombosis397
- fatigue395
- hot flush388
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 1,602 |
| 2005 | 1,529 |
| 2006 | 1,384 |
| 2007 | 949 |
| 2008 | 1,913 |
| 2009 | 4,410 |
| 2010 | 5,905 |
| 2011 | 1,202 |
| 2012 | 754 |
| 2013 | 487 |
| 2014 | 363 |
| 2015 | 389 |
| 2016 | 399 |
| 2017 | 311 |
| 2018 | 237 |
| 2019 | 322 |
| 2020 | 371 |
| 2021 | 224 |
| 2022 | 259 |
| 2023 | 157 |
| 2024 | 132 |
| 2025 | 119 |
| 2026 | 68 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Prempro (Estrogen,Con/M-Progest Acet)
2024 spending
$37.8M
Beneficiaries
19,265
88,870 claims
Per beneficiary
$1,963
$8.25 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $38,655,663 |
| 2021 | $40,112,549 |
| 2022 | $39,740,685 |
| 2023 | $39,672,699 |
| 2024 | $37,818,858 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Estrogen Deficiency and the Origin of Obesity during Menopause.
Lizcano F, Guzmán G · Biomed Res Int 2014 · Systematic Review
- Systematic review and meta-analysis of the effects of menopause hormone therapy on cognition.
Andy C, Nerattini M, Jett S, et al. · Front Endocrinol (Lausanne) 2024 · Meta-Analysis, Systematic Review
- Treatment of urge incontinence in postmenopausal women: A systematic review.
Bapir R, Bhatti KH, Eliwa A, et al. · Arch Ital Urol Androl 2023 · Meta-Analysis, Systematic Review
- Impact of Ketogenic Diet on Weight, Metabolic, and Endocrine Parameters in Women with Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis.
Turetta C, Turetta C, Giannini A, et al. · Gynecol Obstet Invest 2025 · Systematic Review, Meta-Analysis
- Hormone therapy in the postmenopausal years: considering benefits and risks in clinical practice.
Genazzani AR, Monteleone P, Giannini A, et al. · Hum Reprod Update 2021 · Randomized Controlled Trial
- Estrogen for schizophrenia.
Chua WL, de Izquierdo SA, Kulkarni J, et al. · Cochrane Database Syst Rev 2005 · Meta-Analysis, Systematic Review
Sponsor: Pfizer · Also marketed as Premphase 14/14
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.